Schizophrenia Research
Volume 115, Issue 2 , Pages 141-145 , December 2009

Biochemical risk factors for development of obesity in first-episode schizophrenia

  • Robert Bodén

      Affiliations

    • Department of Neuroscience, Psychiatry Ulleråker, Uppsala University Hospital, S-750 17, Sweden
    • Corresponding Author InformationCorresponding author. Fax: +46 18 51 58 10.
    • ,
  • Arvo Haenni

      Affiliations

    • Department of Medical Sciences, Uppsala University Hospital, S-751 85, Sweden
    • ,
  • Leif Lindström

      Affiliations

    • Department of Neuroscience, Psychiatry Ulleråker, Uppsala University Hospital, S-750 17, Sweden
    • ,
  • Johan Sundström

      Affiliations

    • Department of Medical Sciences, Uppsala University Hospital, S-751 85, Sweden

Received 29 May 2009 ,Revised 22 September 2009 ,Accepted 24 September 2009.

References 

  1. Addington J, Saeedi H, Addington D. Weight gain in first-episode psychosis over three years. Schizophr. Res. 2006;86(1–3):335–336
  2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156(11):1686–1696
  3. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr. Serv. 2003;54(4):565–567
  4. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry. 2007;12(8):707–747
  5. Boden R, Sundstrom J, Lindstrom E, Lindstrom L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr. Res. 2009;107(2–3):232–237
  6. Boden R, Sundstrom J, Lindstrom E, Wieselgren IM, Lindstrom L. Five-year outcome of first-episode psychosis before and after the implementation of a modified assertive community treatment programme. Soc. Psychiatry Psychiatr. Epidemiol. 2009;
  7. Choi KM, Lee J, Kim YH, Kim KB, Kim DL, Kim SG, et al. Relation between insulin resistance and hematological parameters in elderly Koreans—Southwest Seoul (SWS) Study. Diabetes Res. Clin. Pract. 2003;60(3):205–212
  8. De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res. 2008;101(1–3):295–303
  9. Facchini FS, Carantoni M, Jeppesen J, Reaven GM. Hematocrit and hemoglobin are independently related to insulin resistance and compensatory hyperinsulinemia in healthy, non-obese men and women. Metabolism. 1998;47(7):831–835
  10. Gould AJ, Williams DE, Byrne CD, Hales CN, Wareham NJ. Prospective cohort study of the relationship of markers of insulin resistance and secretion with weight gain and changes in regional adiposity. Int. J. Obes. Relat. Metab. Disord. 1999;23(12):1256–1261
  11. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int. Clin. Psychopharmacol. 2006;21(2):93–98
  12. Hatta K, Takahashi T, Nakamura H, Yamashiro H, Endo H, Fujii S, et al. Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes. Eur. Arch. Psychiatry Clin. Neurosci. 1998;248(4):180–188
  13. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 2005;150(6):1115–1121
  14. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987–1996. Schizophr. Res. 2002;55(3):277–284
  15. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097
  16. Kuskowska-Wolk A, Karlsson P, Stolt M, Rossner S. The predictive validity of body mass index based on self-reported weight and height. Int. J. Obes. 1989;13(4):441–453
  17. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J. Clin. Psychopharmacol. 2006;26(2):128–134
  18. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353(12):1209–1223
  19. Mardi T, Toker S, Melamed S, Shirom A, Zeltser D, Shapira I, et al. Increased erythropoiesis and subclinical inflammation as part of the metabolic syndrome. Diabetes Res. Clin. Pract. 2005;69(3):249–255
  20. Mathew RJ, Wilson WH. Elevated hematocrit in patients with schizophrenia. Biol. Psychiatry. 1987;22(7):907–910
  21. McGlashan TH, Cleary PA. Clinical laboratory test standards for a sample of schizophrenics. Psychopharmacologia. 1975;44(3):281–285
  22. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2004;27(6):1427–1432
  23. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry. 2007;68(Suppl 4):8–13
  24. Nilsson BM, Forslund AH, Olsson RM, Hambraeus L, Wiesel F-A. Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls. Acta Psychiatr. Scand. 2006;114(1):27–35
  25. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 2000;45(1–2):21–28
  26. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. Bmj. 2000;321(7259):483–484
  27. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, et al. Glucose and lipid disturbances after 1year of antipsychotic treatment in a drug-naive population. Schizophr. Res. 2009;107(2–3):115–121
  28. Ravussin E, Gautier JF. Metabolic predictors of weight gain. Int. J. Obes. Relat. Metab. Disord. 1999;23(Suppl 1):37–41
  29. Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust. N. Z. J. Psychiatry. 2008;42(5):369–381
  30. Rettenbacher MA, Baumgartner S, Eder-Ischia U, Edlinger M, Graziadei I, Hofer A, et al. Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. J. Clin. Psychopharmacol. 2006;26(5):500–503
  31. Saarni SE, Saarni SI, Fogelholm M, Heliovaara M, Perala J, Suvisaari J, et al. Body composition in psychotic disorders: a general population survey. Psychol. Med. 2008;1–10
  32. Saddichha S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J. Clin. Psychopharmacol. 2008;28(1):27–31
  33. Satoh M, Sakuda H, Kobayashi T, Kataoka T, Nakao F, Turale S. Comparison of the body fluid levels in healthy individuals and those with schizophrenia in Japan: using the bioelectrical impedance method. Nurs. Health Sci. 2007;9(3):177–184
  34. Shigetoh Y, Adachi H, Yamagishi S-I, Enomoto M, Fukami A, Otsuka M, et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am. J. Hypertens. 2008;22(2):151–155
  35. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 2007;24(5):481–485
  36. Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr. Res. 2007;93(1–3):90–98
  37. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. N. Engl. J. Med. 1990;322(21):1483–1487
  38. Sundquist J, Johansson SE. The influence of socioeconomic status, ethnicity and lifestyle on body mass index in a longitudinal study. Int. J. Epidemiol. 1998;27(1):57–63
  39. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr. Res. 2004;66(1):51–57
  40. Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension. 2000;36(4):531–537
  41. WHO . Obesity: Preventing and Managing the Global Epidemic. Technical Report series. Geneva: World Health Organization; 2000;
  42. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch. Intern. Med. 2002;162(16):1867–1872
  43. Wu MK, Huang CY, Liou YJ, Wang CK, Lee SD. Glucose–insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. Int. J. Obes. (Lond.). 2008;32(3):436–442
  44. Zahn TP, Carpenter WT, McGlashan TH. Autonomic nervous system activity in acute schizophrenia: I. Method and comparison with normal controls. Arch. Gen. Psychiatry. 1981;38(3):251–258

☆ This report is written according to the STROBE guidelines.

PII: S0920-9964(09)00468-X

doi: 10.1016/j.schres.2009.09.024

Schizophrenia Research
Volume 115, Issue 2 , Pages 141-145 , December 2009

Article Tools

* Image Usage & Resolution